Press release Communiqué de presse

Share the news     Partagez les nouvelles

Email Facebook LinkedIn Twitter

Press release Communiqué de presse


February 13, 2001 13 February, 2001

Benoit La Salle Joins Pheromone Sciences Board of Directors Benoit La Salle Joins Pheromone Sciences Board of Directors


Toronto, Ontario (February 13, 2001) - Pheromone Sciences Corp (CDNX:PHS), is pleased to announce the appointment of Mr. Benoit La Salle to its Board of Directors

Mr. La Salle, a Chartered Accountant, is a member of the Quebec Order of Chartered Accountants, the Canadian Institute of Chartered Accountants, the Order of Chartered Administrators of Quebec and the Quebec Institute of Financial Planners. In 1980, Mr. La Salle founded the firm of Grou, La Salle & Associes, Chartered Accountants. Mr. La Salle holds extensive experience in matters relating to public companies.

Active in the public markets, Mr. La Salle is currently the President and Chief Executive Officer of Semafo Inc., a TSE listing firm engaged in mining activities in West Africa. In addition, he serves on the board of directors of a number of public companies including Bio-Capital and Bridgepoint International Inc. and as both a member of the board of directors and audit committee of The Canam Manac Group, Vasogen Inc., Pebercan Inc., and Electromed Imaging Inc.

"We are delighted to have Benoit La Salle accept a position on the Board of Directors," commented Dr. William Cochrane, Chairman of Pheromone Sciences Corp. "Mr. La Salle adds extensive business experience and financial expertise that will benefit the Company as we continue to advance the commercial development of our products."

Mr. La Salle holds a commerce degree from McGill University and a master of business administration from IMEDE in Switzerland. He is involved in a number of charitable organizations including that of the Ecole Buissoniere Foundation and Foster Parents Plan Canada.

The appointment, which is subject to regulatory approval, is part of an on-going program to enhance the independent nature of the Board. As such, the Board has accepted the resignation of Douglas Marett. Mr. Marett remains a member of senior management retaining the position Vice- President and Chief Scientific Officer.

Pheromone Sciences Corp. is a biotechnology and medical diagnostics device research and development company that focuses on commercializing technologies in the field of human reproduction and sexuality.

Statements contained in this press release, including those pertaining to scientific and clinical research, commercialization plans, strategic alliances, and intellectual property protection, other than statements of historical fact, are forward-looking statements subject to a number of uncertainties that could cause actual results to differ materially from statements made. The Canadian Venture Exchange has not reviewed and does not accept responsibility for the adequacy or the contents of this news release.